Introduction

Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997; 37 Suppl 1: S15–25

Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet 1985; 10: 334–52

Silberstein SD , Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Neurology 1995; 45: 577–84

Peroutka SJ. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine. Neurology 1993; 43 Suppl 3: S34–8

Goadsby PJ , Gundlach AL. Localization of ³H-dihydroer-gotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991; 29: 91–4

Moskowitz MA. The trigeminovascular system. Scientific Basis of Migraine, American Academy of Neurology, 49th Annual Meeting, Boston, 1997; 131: 11–19

Goadsby PJ. Central processing of trigeminovascular inputs: relationship to migraine. Scientific Basis of Migraine, American Academy of Neurology, 49th Annual Meeting, Boston, 1997; 131: 11–19

Diener HC , Jueptner M. Brainstem-cortical generators. Scientific Basis of Migraine, American Academy of Neurology, 49th Annual Meeting, Boston, 1997; 131: 21–6

Ferrari M , Saxena P. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993; 13: 151–65

Silberstein S. Serotonin (5-HT) and migraine. Headache 1994; 34: 408–17

Martin GR. Serotonin receptor involvement in the pathogenesis and treatment of migraine. In: Goadsby PJ , Silberstein SD editors. Headache. Boston: Butterworth-Heinemann, 1997: 25–38

Sicuteri F , Testi A , Anselmi B. Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy Appl Immunol 1961; 19: 55–8

Goadsby PJ. Pathophysiology of migraine: a disease of the brain. In: Goadsby PJ , Silberstein SD editors. Headache. Boston: Butterworth-Heinemann; 1997: 5–24

Rebeck GW , Maynard KI , Hyman BT. Selective 5-HT_1Dalpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA 1994; 91: 3666–9

Hamel E , Fan E , Linville D , Ting V , Villemure J-G , Chia L-S. Expression of mRNA for the serotonin 5-hydroxtryptamine_1Dβ receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 1993; 44: 242–6

Glen R , Martin GR , Hill AP. Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT_1D receptor: discovery of compounds with potential anti-migraine properties. J Med Chem 1995; 38: 3566–80